Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication

Since the approval by WHO of Xpert® MTB/RIF (Cepheid, Sunnyvale, USA, hereafter referred to as ‘Xpert MTB/RIF’) in 2010, significant additional evidence has been generated on its use as initial test for the diagnosis of TB and rifampicin-resistant TB. In recent months new data on the use of Xpert® MTB/RIF Ultra (Cepheid, Sunnyvale, USA, hereafter referred to as ‘Xpert Ultra’) and on the latest version Truenat® MTB and MTB Plus system (Molbio Diagnostics, Goa, India, hereafter referred to as ‘Truenat’) have also become available.